Specific p53 mutations do not impact results of alemtuzumab therapy among patients with chronic lymphocytic leukemia

MeSH terms

• Adult
• Aged
• Alemtuzumab
• Antibodies, Monoclonal, Humanized / administration & dosage
• Antibodies, Monoclonal, Humanized / therapeutic use*
• Antineoplastic Agents / administration & dosage
• Antineoplastic Agents / therapeutic use
• Chromosome Deletion
• Chromosomes, Human, Pair 17 / genetics
• Dose-Response Relationship, Drug
• Drug Administration Schedule
• Female
• Humans
• Kaplan-Meier Estimate
• Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
• Leukemia, Lymphocytic, Chronic, B-Cell / genetics*
• Male
• Middle Aged
• Mutation*
• Retrospective Studies
• Treatment Outcome
• Tumor Suppressor Protein p53 / genetics*